COVID-19 affects people differently. Sometimes it ravishes the immune system, and attacks the lungs, while other cases are asymptomatic and go unnoticed. A recent Newswire press release announced that a Utah-based biotechnology company called Inherent Biosciences received a grant to study epigenetic biomarkers to predict a patient response to COVID-19 infection. The $255,959 grant comes from the National Science Foundation in an effort to develop on-site clinical tests that screen incoming patients and prioritizes hospital resources based on the predicted infection severity.
NSF Granted $256K to Predict Severity of COVID Infections
The goal is to prioritize patients coming into the ER to ensure hospital resources are allocated efficiently.
Sep 15, 2020
Test Your Supply Chain Smarts
Take Healthcare Packaging's supply chain quiz to prove your knowledge!Take Quiz
Discover Our Content Hub
Access Healthcare Packaging's free educational content library!Unlock Learning Here